Filamon Ltd chairman Graham Kelly tells Proactive the company sees itself as a biotech incubator for major pharmaceutical firms. He says its aim is to stop the progression of cancer from a manageable to an unmanageable state. Filamon has assembled a pipeline of three unique drug assets, which all target the inflammatory forces employed by cancer cells to manipulate their environment.
Filamon Ltd on a mission to stop the progression of cancer
